 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural...

Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen

VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D...

Absci to Host R&D Day on October 4, 2023

VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 25th Annual Global Investment ConferenceFireside...

Absci to Participate in Upcoming Investor Conferences

Truist Financial reaffirmed their buy rating on shares of Absci (NASDAQ:ABSI  Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $10.00 price objective on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $4.00 ...

Truist Financial Reiterates Buy Rating for Absci (NASDAQ:ABSI)

HC Wainwright reaffirmed their buy rating on shares of Absci (NASDAQ:ABSI  Free Report) in a research report report published on Tuesday , Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright also issued estimates for Abscis Q3 2023 earnings at ($0....

HC Wainwright Reiterates Buy Rating for Absci (NASDAQ:ABSI)

Truist Financial restated their buy rating on shares of Absci (NASDAQ:ABSI  Free Report) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. Separately, HC Wainwright restated a buy rating and set a $4.00 price ...

Absci (NASDAQ:ABSI) Earns Buy Rating from Truist Financial

HC Wainwright reiterated their buy rating on shares of Absci (NASDAQ:ABSI  Free Report) in a research report sent to investors on Tuesday , Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock. Absci Stock Performance Shares of Absci stock opened at $1.64 on Tuesday...

Absci (NASDAQ:ABSI) Rating Reiterated by HC Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI Research Report) today and set a price target of $4.00. The... H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI &#8211...

H.C. Wainwright Reaffirms Their Buy Rating on AbSci (ABSI)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Absci appoints Jonasson as CFO, CBO

Absci expects cash to fund operations into late 2025

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Watchers	895
52-Wk Low	$1.13
52-Wk High	$3.71

Market Cap	$125.16M
Volume (M)	339,898.00
52-Wk High	$3.71
52-Wk Low	$1.13

ABSI Absci Corp

About

Feed

News

Sentiment

Earnings

Fundamentals